Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistanceAishath Naeem, Jennifer R. Brown, Stacey M. Fernandes et al.|Blood Advances|2022Cited by 79
AKT1-mediated Lamin A/C degradation is required for nuclear degradation and normal epidermal terminal differentiationAishath Naeem, Ryan F.L. O’Shaughnessy|Cell Death and Differentiation|2015Cited by 72
A mechanistic target of rapamycin complex 1/2 (mTORC1)/V-Akt murine thymoma viral oncogene homolog 1 (AKT1)/cathepsin H axis controls filaggrin expression and processing in skin, a novel mechanism for skin barrier disruption in patients with atopic dermatitisAishath Naeem, Ryan F.L. O’Shaughnessy|Journal of Allergy and Clinical Immunology|2016Cited by 47
Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samplesJasneet Kaur Khalsa, Jennifer R. Brown, Justin Cha et al.|Blood|2023Cited by 26
Mutations Detected in Real World Clinical Sequencing during BTK Inhibitor Treatment in CLLJennifer R. Brown, Matthew S. Davids, Kiyomi Mashima et al.|Research Square|2024Cited by 13